Amphastar Pharmaceuticals (AMPH) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 8.6% versus a loss of 54.5%. Over five years, AMPH leads with a +41.9% price change compared with -14.8% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size, while Amphastar Pharmaceuticals is growing revenue faster (-1.7% vs -18.5%).
Amphastar Pharmaceuticals converts more of its revenue into profit, with a net margin of 13.6% versus -511.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | OCUL |
|---|---|---|
| Share price | $28.25 | $5.57 |
| Market cap | $1.20B | $1.23B |
| 1-day change | +0.50% | -4.95% |
| YTD return | +5.49% | -54.12% |
| 1-year return | +8.61% | -54.49% |
| 5-year return | +41.89% | -14.83% |
| P/E ratio (TTM) | 12.96 | — |
| Forward P/E | 8.43 | — |
| EPS (TTM) | $2.18 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $719.89M | $51.95M |
| Revenue growth (YoY) | -1.65% | -18.47% |
| Net income (latest FY) | $98.09M | $-265.94M |
| Gross margin | 49.46% | 87.35% |
| Operating margin | 19.50% | -519.75% |
| Net margin | 13.63% | -511.90% |
| 52-week high | $31.00 | $16.44 |
| 52-week low | $16.65 | $5.54 |
| Distance from 52-week high | -8.87% | -66.12% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -13.27% | +361.94% |
| Average volume | 475.35K | 3.03M |
| Shares outstanding | 42.65M | 220.02M |
| Employees | 1,976 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMPH has outperformed OCUL by 63.1 percentage points over the past year.
- Amphastar Pharmaceuticals is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -511.9 cents for Ocular Therapeutix.
- Amphastar Pharmaceuticals grew revenue faster in its latest fiscal year (-1.65% vs -18.47%).
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
AMPH vs OCUL FAQ
Which is bigger, Amphastar Pharmaceuticals or Ocular Therapeutix?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or OCUL?
AMPH returned +8.61% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.